Document is current
Any future updates will be listed below
-
Authors
Eliason, Laurie
Grant, Laura
Francis, Anya
Cardellino, Anna
Culver, Ken
Chawla, Sant P.
Arbuckle, Rob
Pokras, Shibani
-
Funding
Funding for this research was provided by:
GSK (209386)
- License Information
-
More Information
Article History
Received: 10 August 2021
Accepted: 20 April 2022
First Online: 4 May 2022
Declarations
:
: All participants provided written informed consent before enrolment. The study was approved and overseen by the Western Independent Review Board (reference number: HO-18-19345).
: Not applicable.
: LE, SP, and AC are employees of and hold stocks/stock options in GSK. LG, AF, and RA are employees of Adelphi Values, a health outcomes agency contracted by GSK to conduct the research described here. KC is an employee of GSK, a former employee of Novartis, and owns stocks/shares in GSK. SPC receives grants/consulting fees/honoraria from Amgen, Roche, GSK, Threshold Pharmaceuticals, CytRx Corporation, Ignyta, Immune Design, TRACON Pharma, Karyopharm Therapeutics, Sarcoma Alliance for Research through Collaboration (SARC), Janssen, Advenchen Laboratories, Bayer, InhibRx, NKMax, and Tyme and holds stocks/stock options in AADi, Cellestia Biotech, and Immix BioPharma.
